CJC-1295: What Makes This Peptide Different?
CJC-1295 is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH) ā the natural hormone that tells your pituitary gland to produce and release growth hormone. It's one of the most studied peptides in the GH secretagogue class and is frequently used in research protocols aimed at modulating the somatotropic axis.
How Does CJC-1295 Work?
CJC-1295 binds to GHRH receptors on the pituitary gland, amplifying the natural signal to release growth hormone. Unlike exogenous HGH (which introduces external GH directly), CJC-1295 works through your body's own production system ā stimulating a more physiologic, pulsatile pattern of GH release.
The "no DAC" version (Modified GRF 1-29) has a shorter half-life, producing discrete GH pulses. The DAC version (Drug Affinity Complex) extends the half-life significantly, creating more sustained GH elevation. Most research protocols use the no-DAC version for more controlled, pulse-like release.
Research Applications
GH Axis Modulation
CJC-1295 allows researchers to study the effects of enhanced GH secretion without introducing exogenous GH, maintaining the body's feedback mechanisms and natural pulsatile rhythm.
Body Composition Research
Preclinical and early clinical data suggest GH elevation via GHRH analogues may influence lean mass preservation, fat metabolism, and recovery ā though large-scale RCTs are still limited.
Combination Protocols
CJC-1295 is most commonly combined with ipamorelin ā a pairing that stimulates GH through two distinct pathways (GHRH + ghrelin receptor) for a synergistic effect.
Our CJC-1295 / Ipamorelin blend is currently sold out ā join our newsletter to be notified when it's back in stock. Ipamorelin is available separately ā
All products sold by Tidal Peptides are for research use only. Not for human consumption.